levodopa has been researched along with piperidines in 123 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (17.89) | 18.7374 |
| 1990's | 23 (18.70) | 18.2507 |
| 2000's | 40 (32.52) | 29.6817 |
| 2010's | 35 (28.46) | 24.3611 |
| 2020's | 3 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Lörincz, P; Ludin, HP; Ringwald, E | 1 |
| Colpaert, FC; Lal, H; Niemegeers, C; Wauquier, A | 1 |
| Lippmann, W; Pugsley, TA | 1 |
| Cotzias, GC; Lazarus, CB; Papavasiliou, PS; Tolosa, ES | 1 |
| Chung, PM; Lee, HK; Wang, SC | 1 |
| Gerlach, J | 1 |
| Baran, L; Maj, J; Sowińska, H | 1 |
| Bohmaker, K; Bordi, F; Meller, E | 1 |
| Ekman, A; Eriksson, E | 1 |
| Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| Black, CK; Fadayel, GM; Humphreys, TM; Nieduzak, TR; Schmidt, CJ; Sorensen, SM; Taylor, VL | 1 |
| Humphreys, TM; Schmidt, CJ; Sorensen, SM; Taylor, VL | 1 |
| Abbate, GM; Nieduzak, TR; Schmidt, CJ; Taylor, VL | 1 |
| Bar, M; Graff, E; Isakov, M; Oberman, Z; Rabey, JM; Scharf, M | 1 |
| Villares, JC | 1 |
| Bohmaker, K; Friedhoff, AJ; Goldstein, M; Meller, E; Namba, Y | 1 |
| Jenner, P; Marsden, CD; Nomoto, M | 1 |
| Delwaide, PJ; Maertens de Noordhout, A | 1 |
| Bizière, K; Kan, JP; Roncucci, R; Wermuth, CG; Worms, P | 1 |
| Bliesath, H; Jellinger, K | 1 |
| Como, P; Kurlan, R | 1 |
| Fischer, R; Iizuka, J | 1 |
| Ahlenius, S; Criborn, CO; Henriksson, C; Hillegaart, V | 1 |
| Brown, F; Campbell, W; Mitchell, PJ; Randall, K | 1 |
| Chase, TN | 1 |
| Agid, Y; Illas, A; Lhermitte, F; Quinn, N | 1 |
| Gerstenbrand, F; Gründig, E | 1 |
| Agid, Y; Lhermitte, F; Quinn, N | 1 |
| Alessandria, A; Bonifati, V; Giustini, P; Meco, G | 1 |
| Andersson, KE; Ishizuka, O; Mattiasson, A | 1 |
| de Yebenes, JG; Mena, MA; Neira, WD; Sanchez, V | 1 |
| Achiron, A; Djaldetti, R; Koren, M; Melamed, E; Ziv, I | 1 |
| Bravi, D; Chase, TN; Hoff, JI; Metman, LV; Mouradian, MM; Roberts, JR; Sethy, VH | 1 |
| Brooks, S; Kaur, S; Starr, BS; Starr, MS | 1 |
| Djaldetti, R; Melamed, E; Ziv, I | 1 |
| Andrén, PE; Ekesbo, A; Gunne, LM; Tedroff, J | 1 |
| Carlsson, A; Fasth, KJ; Hartvig, P; Långström, B; Neu, H; Sonesson, C; Tedroff, J; Torstenson, R; Waters, N | 1 |
| Biggs, CS; Fisher, A; Starr, MS | 1 |
| Klockgether, T; Löschmann, PA; Spieker, S | 1 |
| Breit, S; Dichgans, J; Klockgether, T; Spieker, S | 1 |
| Bigge, CF; Boxer, PA; Cai, SX; Gregory, TF; Hawkinson, JE; Konkoy, CS; Meltzer, LT; Serpa, K; Whittemore, ER; Wise, LD; Woodward, RM; Wright, JL; Zhou, ZL | 1 |
| Biggs, CS; Starr, MS | 1 |
| Boxer, PA; Gregory, TF; Meltzer, LT; Serpa, KA; Wise, LD; Wright, JL | 1 |
| Ghaemi, M; Rudolf, J; Schmülling, S | 1 |
| Andersson, KE; Igawa, Y; Ishizuka, O; Nishizawa, O | 1 |
| Andrén, PE; Ekesbo, A; Gunne, LM; Sonesson, C; Tedroff, J | 1 |
| Blanchet, PJ; Chase, TN; Konitsiotis, S; Lamers, E; Verhagen, L | 1 |
| Chambers, LK; Greenamyre, JT; Jaw-Tsai, SS; Menniti, FS; Steece-Collier, K | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Hill, MP; Hille, C; Maneuf, Y; McGuire, S; Nash, JE; Peggs, D | 1 |
| Adams, AC; Keefe, KA; Layer, RT; McCabe, RT | 1 |
| Bangassoro, E; Bédard, PJ; Ekesbo, A; Grégoire, L; Hadj Tahar, A; Svensson, KA; Tedroff, J | 1 |
| Andrén, PE; Gunne, L; Hurd, YL; Pirker, W; Pontén, H; Tedroff, J | 1 |
| Müller, T | 1 |
| Bittkau, S; Bliesath, H; Büttner, U; Fuchs, G; Glass, J; Haller, H; Klockgether, T; Kraus, P; Lachenmayer, L; Müller, D; Müller, T; Przuntek, H; Rathay, B; Sgonina, J; Steinijans, V; Teshmar, E; Ulm, G; Volc, D | 1 |
| Brotchie, JM; Nash, JE | 1 |
| Cimini, MG; Haas, JV; Nichols, NF; Staton, BA; Svensson, KA; Tedroff, J | 1 |
| Chase, TN; Geller, AI; Oh, JD; Zhang, Gr | 1 |
| SOULAIRAC, A; SOULAIRAC, ML | 1 |
| Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D | 1 |
| Ceballos-Baumann, A | 1 |
| Bédard, PJ; Bélanger, N; Darré, A; Grégoire, L; Hadj Tahar, A; Meltzer, L | 1 |
| De Groote, C; Fischer, G; Jenner, P; Kemp, JA; Klockgether, T; Löschmann, PA; Smith, L; Wüllner, U | 1 |
| Ahmed, SM; Chase, TN; Dunbar, GL; Menniti, FS; Oh, JD; Wessell, RH | 1 |
| Brotchie, JM; Crossman, AR; McGuire, S; Menniti, FS; Nash, JE; Ravenscroft, P | 1 |
| Cullen, EI; Hahne, WA; Kirby, L; Kumar, D; Okereke, CS; Pratt, RD | 1 |
| Brotchie, JM; Crossman, AR; Di Marzo, V; Fox, SH; Hill, M; Petrosino, S; van der Stelt, M | 1 |
| Lang, AE | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M | 2 |
| Ambreen, N; Butt, N; Choudhary, MI; Khan, KM; Khan, MT; Maharvi, GM; Perveen, S; Saify, ZS; Supuran, CT | 1 |
| Caroff, SN; Duda, JE; Eisa, M; Gallop, R; Kleiner-Fisman, G; Lorry, A; Martine, R; Stern, MB | 1 |
| Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G | 1 |
| Bishop, C; Rice, KC; Taylor, JL; Ullrich, T; Walker, PD | 1 |
| Brotchie, JM; Millan, MJ; Visanji, NP | 1 |
| Axelsson, J; Bengtsson, E; Bergström, M; Långström, B; Razifar, P; Schneider, H | 1 |
| Hattori, T; Sakakibara, R; Uchiyama, T | 1 |
| Brotchie, JM; Crossman, AR; Hill, MP; McGuire, SG; Millan, MJ; Ravenscroft, P; Rochat, C | 1 |
| Marti, M; Morari, M; Trapella, C; Viaro, R | 1 |
| Bédard, PJ; Belanger, N; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M; Samadi, P | 1 |
| Betz, AJ; Bibbiani, F; Chase, TN; Davis, RE; Kielaite, A; Salamone, JD; Vanover, KE; Weber, SM; Weiner, DM | 1 |
| Belkhir, S; Di Paolo, T; Dridi, M; Grégoire, L; Meltzer, LT; Morissette, M; Ouattara, B; Samadi, P | 1 |
| Gunzler, SA; Hogarth, P; Jamerson, B; Kirchhoff, T; Krams, M; Landen, JW; Menniti, FS; Nutt, JG; Weaver, JL | 1 |
| Brotchie, JM; de Bie, RM; Fox, SH; Johnston, TH; McCreary, AC; Visanji, NP | 1 |
| Cassin, J; Harris, O; Kelsey, JE | 1 |
| Addy, C; Assaid, C; Ellenbogen, A; Gottesdiener, K; Herring, WJ; Hreniuk, D; Jinnah, HA; Kirby, L; Leibowitz, MT; Stewart, RM; Stoch, SA; Stroh, M; Tarsy, D; Tetrud, J; Wagner, J; Xu, Y | 1 |
| Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK | 1 |
| Bélanger, N; Di Paolo, T; Hadj Tahar, A; Morissette, M; Samadi, P | 1 |
| Marti, M; Morari, M; Viaro, R | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; McIldowie, MJ; Piggott, MJ | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hoyer, D; Morissette, M; Ouattara, B | 1 |
| Schneemilch, C | 1 |
| Dowd, E; Finn, DP; Gorman, AM; Walsh, S | 1 |
| Konitsiotis, S; Maranis, S; Stamatis, D; Tsironis, C | 1 |
| Kullingsjö, J; Ponten, H; Sonesson, C; Tedroff, J; Waters, N; Waters, S | 1 |
| Auberson, YP; Budri, M; Calcagno, M; Dekundy, A; Mabrouk, OS; Mela, F; Morari, M; Parsons, CG; Viaro, R | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
| Bézard, E; Björklund, A; Carta, M; Li, Q; Muñoz, A; Pioli, EY; Porras, G; Tronci, E | 1 |
| di Marzo, V; Freestone, PS; Guatteo, E; Lipski, J; Mercuri, NB; Piscitelli, F | 1 |
| Armentero, MT; Baqi, Y; Bonaventura, J; Canela, EI; Casadó, V; Cortés, A; Costa, G; Farré, D; Franco, R; Lanciego, JL; Lluís, C; Mallol, J; Martínez-Pinilla, E; McCormick, P; Müller, CE; Pinna, A; Sánchez, M; Simola, N | 1 |
| Lettow, I; Röther, J | 1 |
| Iravani, M; Jackson, M; Jenner, P; McCreary, AC; Papathanou, M; Rose, S; Stockwell, K; Strang, I; Zeng, BY | 1 |
| Downey, P; Michel, A; Nicolas, JM; Scheller, D | 1 |
| Ba, M; Kong, M; Liu, C; Qiu, H; Zhang, H; Zhang, Y | 1 |
| Cenci, MA; Iderberg, H; McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Akita, H; Habata, T; Igarashi, M; Noda, K; Ogata, M; Saji, M | 1 |
| Cui, G; Hua, F; Shen, X; Shi, H; Wang, X; Yang, X; Zhang, S; Zhang, W; Zhang, Z; Zhao, H; Zu, J | 1 |
| Bardin, L; Cenci, MA; Depoortère, R; Iderberg, H; Kleven, MS; Koek, W; McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Newman-Tancredi, A | 1 |
| Cramer, SC | 1 |
| McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Baba, T; Inoue, Y; Kohno, M; Miyaji, A | 1 |
| Gore, C; Wu, C | 1 |
| Stahl, SM | 1 |
| Durando, M; Kim, JS; Tiu, H | 1 |
| Chen, K; Shen, X; Ye, M | 1 |
| Arcuri, L; Brambilla, R; Fasano, S; Frassineti, M; Journigan, BV; Mercatelli, D; Meyer, ME; Morari, M; Morella, I; Novello, S; Pisanò, CA; Polgar, WE; Zaveri, NT | 1 |
| Challa, JA; Harewood Smith, AN; Silver, MA | 1 |
| Barton, ME; Burn, DJ; Dukes, GE; Gibson, RA; Hellström, PM; Marrinan, SL; Nyholm, D; Otiker, T; Richards, DB; Sarai, BK; Vasist, LS | 1 |
| Brys, I; Halje, P; Newman-Tancredi, A; Petersson, P; Scheffer-Teixeira, R; Varney, M | 1 |
| Arias-Montaño, JA; Avila-Luna, A; Bueno-Nava, A; Gálvez-Rosas, A; Montes, S; Ríos, C | 1 |
| Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A | 1 |
| Beardsley, PM; Bergman, J; Depoortère, R; Desai, RI; Newman-Tancredi, A; Paronis, CA; Varney, MA; Walentiny, DM | 1 |
| Komatsu, K; Takahashi, M; Ueda, A | 1 |
6 review(s) available for levodopa and piperidines
| Article | Year |
|---|---|
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Cisapride; Drug Therapy, Combination; Gastric Emptying; Humans; Injections, Intramuscular; Intestinal Absorption; Levodopa; Parasympathomimetics; Parkinson Disease; Piperidines | 1996 |
Non-dopaminergic drug treatment of Parkinson's disease.
Topics: Adenosine; Adrenergic alpha-Antagonists; Body Weight; Cholinergic Antagonists; Homocysteine; Humans; Levodopa; Methionine; N-Methylaspartate; Parkinson Disease; Piperidines; Serotonin Receptor Agonists | 2001 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines | 2003 |
[Drug treatment for geriatric urinary disorders; current concept].
Topics: Aged; Aged, 80 and over; Amantadine; Cerebral Infarction; Cholinergic Antagonists; Cognition Disorders; Deamino Arginine Vasopressin; Diagnosis, Differential; Donepezil; Humans; Indans; Levodopa; Piperidines; Quality of Life; Serotonin Agents; Urination Disorders | 2006 |
Drugs to Enhance Motor Recovery After Stroke.
Topics: Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Humans; Indans; Levodopa; Motor Activity; Motor Skills; Piperidines; Recovery of Function; Selective Serotonin Reuptake Inhibitors; Stroke; Stroke Rehabilitation | 2015 |
Medical Therapies of Amblyopia: Translational Research to Expand Our Treatment Armamentarium.
Topics: Amblyopia; Carbidopa; Cholinesterase Inhibitors; Donepezil; Dopamine Agonists; Drug Combinations; Fluoxetine; Humans; Indans; Levodopa; Neuronal Plasticity; Piperidines; Selective Serotonin Reuptake Inhibitors; Translational Research, Biomedical; Visual Cortex | 2016 |
16 trial(s) available for levodopa and piperidines
| Article | Year |
|---|---|
Bromocriptine in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Piperidines; Thioxanthenes; Trihexyphenidyl | 1978 |
Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 1987 |
[Modification of Parkinson tremor by budipine. A comparative study with amantadine].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines; Random Allocation | 1986 |
Bromocriptine and domperidone in the treatment of Parkinson disease.
Topics: Benzimidazoles; Bromocriptine; Domperidone; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Piperidines; Vomiting | 1981 |
[Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)].
Topics: Amantadine; Amino Acids; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Piperidines | 1980 |
Effect of cisapride on response fluctuations in Parkinson's disease.
Topics: Aged; Cisapride; Drug Therapy, Combination; Gastric Emptying; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Piperidines; Reaction Time | 1995 |
Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Piperidines | 1994 |
The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; N-Methylaspartate; Parkinson Disease; Pilot Projects; Piperidines; Severity of Illness Index | 1999 |
Tremorlytic activity of budipine in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Electromyography; Female; Humans; Levodopa; Male; Parkinson Disease; Piperidines; Tremor | 1999 |
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines; Treatment Outcome | 2002 |
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cholinesterase Inhibitors; Cross-Over Studies; Donepezil; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 2004 |
Treatment of levodopa-induced dyskinesias with donepezil.
Topics: Aged; Antiparkinson Agents; Donepezil; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Male; Middle Aged; Nootropic Agents; Piperidines | 2006 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome | 2006 |
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.
Topics: Aged; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Dyskinesias; Excitatory Amino Acid Antagonists; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Piperidines; Severity of Illness Index | 2008 |
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hypertension; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Piperidines; Pyrimidines; Receptors, N-Methyl-D-Aspartate | 2009 |
A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piperidines; Statistics, Nonparametric; Treatment Outcome | 2018 |
101 other study(ies) available for levodopa and piperidines
| Article | Year |
|---|---|
Reversal by a central antiacetylcholine drug of pimozide-induced inhibition of mouse-jumping in amphetamine-dopa treated mice.
Topics: Acetylcholine; Amphetamine; Animals; Dexetimide; Levodopa; Male; Mice; Motor Activity; Pimozide; Piperidines; Time Factors | 1975 |
1-[2-Amino-1-[1-(naphthyloxy)methyl] ethyl] piperidine hydrochloride: specific inhibition of brain serotonin uptake and related activities.
Topics: 5-Hydroxytryptophan; Amides; Animals; Brain; Catecholamines; Cerebral Cortex; Drug Interactions; Fenfluramine; In Vitro Techniques; Levodopa; Male; Mice; Myocardium; Oxotremorine; p-Chloroamphetamine; Piperidines; Rats; Serotonin; Synaptosomes | 1977 |
Antagonism by piperidine of levodopa effects in Parkinson disease.
Topics: Aged; Chemical Phenomena; Chemistry; Dose-Response Relationship, Drug; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 1977 |
Mechanism of antiemetic action of penfluridol in the dog.
Topics: Administration, Oral; Animals; Antiemetics; Apomorphine; Dogs; Drug Antagonism; Female; Injections, Intravenous; Injections, Intraventricular; Levodopa; Male; Medulla Oblongata; Penfluridol; Piperidines | 1978 |
The relationship between parkinsonism and tardive dyskinesia.
Topics: Age Factors; Aminobutyrates; Baclofen; Basal Ganglia; Biperiden; Choline; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Methyltyrosines; Mouth; Parkinson Disease; Piperidines; Tranquilizing Agents | 1977 |
Influence of WA-335, a factor which blocks serotonin receptors, on neuroleptic-induced catalepsy.
Topics: Amantadine; Animals; Anthracenes; Catalepsy; Drug Synergism; Female; Humans; Levodopa; Male; Physostigmine; Piperidines; Rats; Receptors, Drug; Reserpine; Serotonin; Tranquilizing Agents | 1976 |
The effects of pertussis toxin on dopamine D2 and serotonin 5-HT1A autoreceptor-mediated inhibition of neurotransmitter synthesis: relationship to receptor reserve.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Brain; Dopamine Agents; GTP-Binding Proteins; Levodopa; Male; Neurotransmitter Agents; Pertussis Toxin; Piperidines; Quinolines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Serotonin; Ribose; Virulence Factors, Bordetella | 1992 |
Effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on the prolactin suppression induced by a series of full and partial dopamine D2 receptor agonists in male rats.
Topics: 4-Butyrolactone; Adrenergic alpha-Antagonists; Animals; Apomorphine; Dopamine Agents; Ergolines; Levodopa; Male; Piperidines; Prolactin; Quinolines; Rats; Rats, Sprague-Dawley | 1992 |
A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Pilot Projects; Piperidines; Receptors, N-Methyl-D-Aspartate | 1992 |
The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine.
Topics: 3,4-Methylenedioxyamphetamine; alpha-Methyltyrosine; Animals; Brain; Corpus Striatum; Dopamine; Electrophysiology; Levodopa; Male; Methyltyrosines; Neurons; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Serotonin Antagonists | 1992 |
5-HT2 receptor antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis.
Topics: Action Potentials; Amphetamines; Animals; Apomorphine; Carbidopa; Dopamine; Dopamine Antagonists; Fenclonine; Levodopa; Male; Neurons; Piperidines; Rats; Rats, Inbred Strains; Ritanserin | 1992 |
5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa.
Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; Animals; Anti-Arrhythmia Agents; Brain; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Haloperidol; Homovanillic Acid; Levodopa; Male; Nomifensine; Piperidines; Rats; Rats, Inbred Strains; Ritanserin; Serotonin Antagonists; Stereoisomerism; Time Factors | 1991 |
Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinson's disease.
Topics: Administration, Oral; Aged; Amantadine; Biperiden; Bromocriptine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Piperidines | 1990 |
[L-dopa, biperiden and sebum excretion in Parkinson disease].
Topics: Aged; Aged, 80 and over; Aromatic-L-Amino-Acid Decarboxylases; Biperiden; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines; Sebum; Sex Factors | 1989 |
Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
Topics: 4-Butyrolactone; Adrenergic alpha-Antagonists; Animals; Apomorphine; Corpus Striatum; Dihydroxyphenylalanine; Homeostasis; Hydrazines; Levodopa; Male; Piperidines; Quinolines; Rats; Rats, Inbred Strains; Receptors, Dopamine | 1987 |
Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callitrichinae; Female; Isomerism; Levodopa; Male; Motor Activity; Piperidines; Pyridines; Receptors, Dopamine; Time Factors | 1986 |
Open pilot trial of ritanserin in parkinsonism.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pilot Projects; Piperidines; Ritanserin | 1986 |
SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Body Temperature; Catalepsy; Clorgyline; Drug Interactions; Female; Haloperidol; Imipramine; Levodopa; Male; Mice; Moclobemide; Monoamine Oxidase Inhibitors; Motor Activity; Nomifensine; Oxotremorine; Pargyline; Piperidines; Pyridazines; Rats; Rats, Inbred Strains; Reserpine; Selegiline; Stereotyped Behavior | 1987 |
Drug-induced alzheimerism.
Topics: Aged; Alzheimer Disease; Biperiden; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Piperidines | 1988 |
Partial protection against hyperbaric oxygen induced convulsions by dopaminergic agents in mice: possible involvement of autoreceptors?
Topics: Animals; Antiparkinson Agents; Apomorphine; Body Temperature; Dose-Response Relationship, Drug; Haloperidol; Hyperbaric Oxygenation; Levodopa; Male; Mice; Mice, Inbred CBA; Piperidines; Reaction Time; Receptors, Dopamine; Respiration; Seizures | 1987 |
Dopamine autoreceptors and the effects of drugs on locomotion and dopamine synthesis.
Topics: alpha-Methyltyrosine; Animals; Dopamine; Levodopa; Locomotion; Male; Methyltyrosines; Mice; Mice, Inbred Strains; Piperidines; Rats; Rats, Inbred Strains; Receptors, Dopamine | 1985 |
Clinical studies of dopaminergic mechanisms.
Topics: Antiparkinson Agents; Dioxoles; Dopamine; Drug Evaluation; Haloperidol; Homovanillic Acid; Humans; Levodopa; Parkinson Disease; Piperidines; Probenecid; Pyrimidines | 1974 |
[Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benzimidazoles; Bromocriptine; Domperidone; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 1981 |
Risperidone for hallucinations in levodopa-treated Parkinson's disease patients.
Topics: Aged; Antipsychotic Agents; Hallucinations; Humans; Isoxazoles; Levodopa; Parkinson Disease; Piperidines; Risperidone | 1994 |
Effects of neurokinin receptor antagonists on L-dopa induced bladder hyperactivity in normal conscious rats.
Topics: Animals; Benzamides; Consciousness; Female; Levodopa; Neurokinin A; Piperidines; Quinuclidines; Rats; Rats, Sprague-Dawley; Urinary Bladder; Urodynamics | 1995 |
The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease.
Topics: Aged; Cisapride; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Piperidines; Psychomotor Performance | 1995 |
Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Biogenic Monoamines; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Efferent Pathways; Excitatory Amino Acid Antagonists; Levodopa; Locomotion; Male; Mice; Mice, Inbred Strains; Motor Neurons; Parkinson Disease; Phenethylamines; Piperidines; Receptors, Dopamine D1; Reserpine; Sympatholytics | 1996 |
(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Carbidopa; Dopamine Antagonists; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Posture; Raclopride; Salicylamides | 1997 |
Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity.
Topics: Animals; Biopterins; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Antagonists; Female; Levodopa; Macaca mulatta; Piperidines; Reference Values; Tomography, Emission-Computed; Tyrosine | 1998 |
The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dopamine; Drug Synergism; Kinetics; Levodopa; Male; Microdialysis; Piperidines; Rats; Rats, Wistar; Reserpine; Substantia Nigra; Time Factors | 1998 |
Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines.
Topics: Animals; Antiparkinson Agents; Drug Synergism; Electrophysiology; Excitatory Amino Acid Antagonists; In Vitro Techniques; Levodopa; Male; Oocytes; Oxidopamine; Phenols; Piperidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Xenopus laevis | 1999 |
Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Levodopa; Male; Microdialysis; Piperidines; Rats; Rats, Wistar; Reserpine; Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase | 1999 |
Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists.
Topics: Animals; Disease Models, Animal; Imidazoles; Levodopa; Ligands; Molecular Structure; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyrazoles; Pyrroles; Rats; Receptors, N-Methyl-D-Aspartate | 1999 |
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Olanzapine; Paranoid Disorders; Parkinson Disease; Piperidines; Pirenzepine; Selegiline; Severity of Illness Index | 1999 |
Role of supraspinal tachykinins for volume- and L-dopa-induced bladder activity in normal conscious rats.
Topics: Animals; Benzamides; Brain; Female; Indoles; Injections, Intraventricular; Isoindoles; Levodopa; Methylene Blue; Neurokinin-1 Receptor Antagonists; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-2; Reference Values; Tachykinins; Tissue Distribution; Urinary Bladder; Urine | 2000 |
Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.
Topics: Adamantane; Animals; Apomorphine; Benzazepines; Benzopyrans; Callithrix; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Quinpirole; Rotation | 2000 |
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Receptors, AMPA; Severity of Illness Index | 2000 |
Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Haloperidol; Levodopa; Macaca mulatta; Male; Parkinson Disease, Secondary; Piperidines; Rats; Rats, Inbred F344; Reaction Time; Receptors, N-Methyl-D-Aspartate | 2000 |
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dopamine Agents; Excitatory Amino Acid Antagonists; Levodopa; Motor Activity; Parkinson Disease; Parkinson Disease, Secondary; Piperidines | 2000 |
Effects of conantokins on L-3,4-dihydroxyphenylalanine-induced behavior and immediate early gene expression.
Topics: Animals; Antiparkinson Agents; Conotoxins; DNA-Binding Proteins; Drug Interactions; Early Growth Response Protein 1; Excitatory Amino Acid Antagonists; Gene Expression; Genes, fos; Genes, Immediate-Early; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Levodopa; Male; Mollusk Venoms; Peptides; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Transcription Factors | 2000 |
Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Piperidines; Receptors, Dopamine D2 | 2001 |
Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.
Topics: Animals; Autoradiography; Callithrix; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Enkephalins; Female; In Situ Hybridization; Injections, Subcutaneous; Levodopa; Ligands; Male; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Protein Precursors; Putamen; RNA, Messenger; Tritium | 2001 |
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Microinjections; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Piperidines; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2002 |
PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Quinpirole; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics | 2002 |
Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Enzyme Inhibitors; Gene Transfer, Horizontal; Genetic Vectors; Herpesvirus 1, Human; Immunohistochemistry; Levodopa; Male; Models, Animal; Motor Activity; Neurons; Parkinsonian Disorders; Phosphorylation; Piperidines; Protein Kinase C; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Time Factors | 2003 |
[ACTION OF CERTAIN L-DOPA/5-HTP DECARBOXYLASE INHIBITORS ON HYPOTHALAMO-HYPOPHYIAL NEUROSECRETION IN THE RAT].
Topics: 5-Hydroxytryptophan; Acetylcholine; Aromatic Amino Acid Decarboxylase Inhibitors; Carboxy-Lyases; Cinnamates; Dopa Decarboxylase; Enzyme Inhibitors; Hypothalamo-Hypophyseal System; Levodopa; Methyldopa; Neurosecretion; Pharmacology; Piperidines; Rats; Research; Serotonin | 1964 |
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Chemistry; Cannabinoid Receptor Modulators; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Dyskinesias; Endocannabinoids; Gas Chromatography-Mass Spectrometry; Levodopa; Male; Morpholines; Mouth; Naphthalenes; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Raclopride; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Substantia Nigra; Time Factors | 2003 |
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Topics: Animals; Benzoxazoles; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Macaca fascicularis; Parkinson Disease; Piperidines; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2004 |
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phenols; Piperidines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate | 2004 |
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Topics: Animals; Excitatory Amino Acid Antagonists; Functional Laterality; Levodopa; Locomotion; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rotation; Serine; Stereotyped Behavior; Sympathectomy, Chemical | 2004 |
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Range of Motion, Articular; Receptors, N-Methyl-D-Aspartate; Treatment Failure | 2004 |
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
Topics: Animals; Arachidonic Acids; Callithrix; Cannabinoid Receptor Modulators; Dyskinesia, Drug-Induced; Endocannabinoids; Female; gamma-Aminobutyric Acid; Glycerides; Levodopa; Male; MPTP Poisoning; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2005 |
Treatment of progressive supranuclear palsy and corticobasal degeneration.
Topics: Amantadine; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Donepezil; Dopamine Agents; Dopamine Agonists; Dystonia; Globus Pallidus; Humans; Indans; Levodopa; Nerve Degeneration; Piperidines; Substantia Nigra; Supranuclear Palsy, Progressive | 2005 |
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Topics: Animals; Antiparkinson Agents; Benserazide; Benzoxazoles; Corpus Striatum; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Protein Precursors; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2006 |
Tyrosinase inhibition: conformational analysis based studies on molecular dynamics calculations of bipiperidine based inhibitors.
Topics: Enzyme Inhibitors; Levodopa; Models, Molecular; Molecular Structure; Monophenol Monooxygenase; Piperidines; Quantitative Structure-Activity Relationship; Substrate Specificity | 2005 |
Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat.
Topics: Analysis of Variance; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Fluorobenzenes; Functional Laterality; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Rotarod Performance Test; Serotonin Antagonists; Stereotyped Behavior | 2006 |
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzoxazoles; Denervation; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Image Processing, Computer-Assisted; In Situ Hybridization; Levodopa; Macaca fascicularis; Motor Activity; Neuroprotective Agents; Oligonucleotide Probes; Ovariectomy; Parkinson Disease, Secondary; Piperidines; Pyrimidines; Receptor, Adenosine A2A; Receptors, N-Methyl-D-Aspartate; Triazoles | 2006 |
Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Biogenic Monoamines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Hyperkinesis; Indoles; Levodopa; Male; Motor Activity; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Reserpine; Time Factors | 2006 |
A new application of pre-normalized principal component analysis for improvement of image quality and clinical diagnosis in human brain PET studies--clinical brain studies using [11C]-GR205171, [11C]-L-deuterium-deprenyl, [11C]-5-Hydroxy-L-Tryptophan, [11
Topics: Antiemetics; Brain; Brain Mapping; Carbon Radioisotopes; Deuterium; Humans; Image Processing, Computer-Assisted; Levodopa; Piperidines; Positron-Emission Tomography; Selegiline; Tetrazoles | 2006 |
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Indoles; Levodopa; Motor Activity; MPTP Poisoning; Oxazines; Piperidines; Receptors, Dopamine D2; Receptors, Dopamine D3; Time Factors | 2006 |
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Bicuculline; Drug Synergism; Drug Therapy, Combination; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Injections; Levodopa; Male; Microdialysis; Motor Activity; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Perfusion; Piperidines; Postural Balance; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Sodium Channel Blockers; Stereotaxic Techniques; Substantia Nigra; Tetrodotoxin; Thalamus | 2007 |
Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Benzoxazoles; Binding, Competitive; Bridged Bicyclo Compounds, Heterocyclic; Convulsants; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Flunitrazepam; GABA Modulators; Isotopes; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Binding; Radiography; Receptors, GABA; Substantia Nigra | 2008 |
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Topics: Animals; Data Interpretation, Statistical; Dopamine Agents; Dyskinesia, Drug-Induced; Jaw; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Piperidines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Tremor; Urea | 2008 |
Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.
Topics: Animals; Autoradiography; Behavior, Animal; Benserazide; Benzoxazoles; Cabergoline; Corpus Striatum; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Ergolines; Female; Humans; Levodopa; Macaca fascicularis; MPTP Poisoning; Ovariectomy; Piperidines; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate | 2009 |
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benzimidazoles; Callithrix; Disability Evaluation; Disease Models, Animal; Drug Synergism; Levodopa; MPTP Poisoning; Nociceptin; Opioid Peptides; Piperidines; Time Factors | 2008 |
The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Hypokinesia; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors | 2010 |
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Ergolines; Female; Glycogen Synthase Kinase 3; Levodopa; Macaca fascicularis; Oncogene Protein v-akt; Parkinsonian Disorders; Phosphorylation; Piperidines; Serine; Signal Transduction; Statistics as Topic | 2010 |
Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
Topics: Amisulpride; Animals; Antiparkinson Agents; Benzimidazoles; Benzothiazoles; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neural Inhibition; Nociceptin; Opioid Peptides; Parkinsonian Disorders; Piperidines; Pramipexole; Pyridines; Reaction Time; Receptors, Dopamine D3; Sulpiride | 2010 |
Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Piperidines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Thiazoles | 2010 |
Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Autoradiography; Benzoxazoles; Brain; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Imidazoles; Levodopa; Ligands; Macaca fascicularis; MPTP Poisoning; Piperidines; Quinazolines; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate | 2010 |
[General anaesthesia for neurological diseases].
Topics: Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Intravenous; Autonomic Nervous System; Brain; Bromocriptine; Dopamine Agonists; Humans; Intubation; Levodopa; Monoamine Oxidase Inhibitors; Muscle Relaxants, Central; Nervous System Diseases; Neurodegenerative Diseases; Neurosurgery; Parkinson Disease; Piperidines; Premedication; Preoperative Care; Propofol; Remifentanil; Selegiline; Stereotaxic Techniques; Syndrome | 2010 |
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Infusions, Intraventricular; Levodopa; Male; Oxidopamine; Phenols; Piperidines; Putamen; Quinoxalines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus; Thiazoles | 2012 |
The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model.
Topics: Animals; Central Nervous System Sensitization; Dopamine; Dopamine Agents; Levodopa; Locomotion; Male; Oxidopamine; Piperidines; Rats; Rats, Sprague-Dawley; Rotation; Time Factors | 2013 |
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Phenols; Piperidines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2013 |
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes | 2013 |
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists | 2013 |
Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta.
Topics: Animals; Arachidonic Acids; Benzofurans; Calcium; Cannabinoid Receptor Antagonists; Central Nervous System Agents; Dopamine; Dopamine Agents; Dopaminergic Neurons; Endocannabinoids; Glutamic Acid; Guanosine Diphosphate; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Levodopa; Neurons; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, Metabotropic Glutamate; Rimonabant; Substantia Nigra; Synaptic Transmission; Thionucleotides | 2014 |
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Cannabinoid Receptor Antagonists; Cholinesterase Inhibitors; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Rimonabant; Tacrine; Time Factors; Tremor | 2014 |
[Medical treatment of Parkinson's disease in elderly and multimorbid patients].
Topics: Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Dopamine Agonists; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Piperidines | 2014 |
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Dyskinesias; Histamine Agonists; Imidazoles; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Wistar | 2014 |
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Benzothiazoles; Drug Therapy, Combination; Levodopa; Mass Spectrometry; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Purines; Pyrimidines; Rats; Receptors, N-Methyl-D-Aspartate; Triazoles | 2014 |
NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Tyrosine | 2015 |
Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperidines; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tyrosine 3-Monooxygenase | 2015 |
The NR2B antagonist, ifenprodil, corrects the l-DOPA-induced deficit of bilateral movement and reduces c-Fos expression in the subthalamic nucleus of hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Brain; Forelimb; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Subthalamic Nucleus | 2015 |
Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Gene Expression Regulation; Indoles; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neurokinin-1 Receptor Antagonists; Oxidopamine; Parkinson Disease; Piperidines; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2015 |
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Haloperidol; Levodopa; Movement; Neurotransmitter Agents; Oxidopamine; Piperidines; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Serotonin Syndrome; Swimming; Vocalization, Animal | 2015 |
The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Piperidines; Pyrimidines; Serotonin 5-HT1 Receptor Agonists; Severity of Illness Index | 2015 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists | 2016 |
Singlet oxygen generation during the oxidation of L-tyrosine and L-dopa with mushroom tyrosinase.
Topics: Agaricales; Electron Spin Resonance Spectroscopy; Indolequinones; Levodopa; Melanins; Monophenol Monooxygenase; Oxidation-Reduction; Piperidines; Singlet Oxygen; Superoxides; Tyrosine | 2016 |
Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.
Topics: Antiparkinson Agents; Antipsychotic Agents; Brain; Dopamine; Humans; Levodopa; Lewy Bodies; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Serotonin; Urea | 2016 |
Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury.
Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Carbidopa; Cholinesterase Inhibitors; Crohn Disease; Donepezil; Drug Combinations; Fluid Therapy; Humans; Indans; Kidney Calculi; Levodopa; Male; Parkinson Disease; Piperidines; Severity of Illness Index; Sulfasalazine; Ultrasonography | 2017 |
Anesthetic management for retrieval of a large aspirated denture in a patient with Parkinson's disease.
Topics: Aged, 80 and over; Anesthesia; Bronchoscopes; Bronchoscopy; Dentures; Etomidate; Foreign Bodies; Humans; Hypnotics and Sedatives; Levodopa; Male; Parkinson Disease; Piperidines; Remifentanil; Respiratory Aspiration; Trachea | 2017 |
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetamides; Animals; Antiparkinson Agents; Corpus Striatum; Cricetinae; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Nociceptin Receptor; Oxidopamine; Phosphorylation; Piperidines; Radioligand Assay; Rats; Receptors, Opioid | 2018 |
Neither Cholinergic Nor Dopaminergic Enhancement Improve Spatial Working Memory Precision in Humans.
Topics: Acetylcholine; Adolescent; Adult; Carbidopa; Donepezil; Dopamine; Double-Blind Method; Drug Combinations; Female; Humans; Indans; Levodopa; Male; Memory, Short-Term; Neuropsychological Tests; Nootropic Agents; Piperidines; Psychometrics; Spatial Memory; Treatment Failure; Visual Perception; Young Adult | 2017 |
Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT
Topics: Animals; Basal Ganglia; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Electric Stimulation; Evoked Potentials; Female; Levodopa; Neural Pathways; Parkinson Disease, Secondary; Piperazines; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thalamus | 2018 |
Chronic administration of the histamine H
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Histamine Agonists; Imidazoles; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Wistar; Receptors, Histamine H3; Substantia Nigra | 2019 |
The selective 5-HT
Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Serotonin 5-HT1 Receptor Agonists | 2020 |
NLX-112, a highly selective 5-HT
Topics: Animals; Humans; Levodopa; Macaca; Male; Piperidines; Pyridines; Rats; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2022 |
[Abnormal posture of the trunk related to donepezil hydrochloride: report of 2 cases].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Levodopa; Male; Movement Disorders; Piperidines; Posture | 2023 |